Washington, DC – Members of the Obesity Care Continuum (OCC) are pleased with the FDA’s Advisory Committee near unanimous vote to approve QNEXA, a new drug to treat those affected by obesity and obesity-related co-morbidities, such as Type 2 diabetes, hypertension and more. “The robust discussion by the panel surrounding both the risks and benefits
Read Article